Pharmacotherapy for COVID-19 treatment in patients with renal impairment: a updated review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | |
Tipo de documento: | preprint |
Idioma: | por |
Título da fonte: | SciELO Preprints |
Texto Completo: | https://preprints.scielo.org/index.php/scielo/preprint/view/384 |
Resumo: | COVID-19 has been identified the cause of several cases of pneumonia in China. The etiologic agent of the disease (SARS-CoV-2 virus) has a binding structure to the angiotensin-converting enzyme 2 (ACE2) receptor, allowing entry into cells that express ACE2, such as pulmonary alveolar epithelial cells. However, studies also show the possibility of damage of renal cells since these cells express high levels of ACE2. Currently, there is no evidence to indicate a specific treatment for COVID-19. Several drugs have been used and some of them may altered the elimination process in patients with renal impairment. To date, there are no studies that assist health professionals in dosing adjustment of these drugs. Thus, this study aimed to review and discuss the issue, considering the factors related to kidney injury in COVID-19, as well as pharmacokinetic aspects and dose recommendations of majority of drugs used for COVID-19. |
id |
SCI-1_4c1f1db615d0bf85299ae145928462d8 |
---|---|
oai_identifier_str |
oai:ops.preprints.scielo.org:preprint/384 |
network_acronym_str |
SCI-1 |
network_name_str |
SciELO Preprints |
repository_id_str |
|
spelling |
Pharmacotherapy for COVID-19 treatment in patients with renal impairment: a updated reviewMedicamentos utilizados no tratamento da COVID-19 em pacientes com insuficiência renal: uma atualizaçãoCOVID-19insuficiência renaltratamento farmacológicoajuste de doseCOVID-19renal insufficiencydrug therapydosing adjustmentsCOVID-19 has been identified the cause of several cases of pneumonia in China. The etiologic agent of the disease (SARS-CoV-2 virus) has a binding structure to the angiotensin-converting enzyme 2 (ACE2) receptor, allowing entry into cells that express ACE2, such as pulmonary alveolar epithelial cells. However, studies also show the possibility of damage of renal cells since these cells express high levels of ACE2. Currently, there is no evidence to indicate a specific treatment for COVID-19. Several drugs have been used and some of them may altered the elimination process in patients with renal impairment. To date, there are no studies that assist health professionals in dosing adjustment of these drugs. Thus, this study aimed to review and discuss the issue, considering the factors related to kidney injury in COVID-19, as well as pharmacokinetic aspects and dose recommendations of majority of drugs used for COVID-19.O COVID-19 foi identificado como a causa de vários casos de pneumonia na China. O agente causador da doença (SARS-CoV-2) possui uma estrutura de ligação ao receptor da enzima de conversão da angiotensina 2 (ACE2), permitindo a entrada em células que expressam ACE2, como as células epiteliais alveolares pulmonares. Porém, estudos também indicam a possibilidade de lesão das células renais uma vez que estas células expressam altos níveis de ACE2. Atualmente, não existem evidências para a indicação de um tratamento específico para a COVID-19. Vários medicamentos vêm sendo utilizados e alguns destes podem ter o processo de eliminação alterados em pacientes com comprometimento renal. Até o momento, não há estudos que auxiliem os profissionais de saúde no ajuste de dose destes medicamentos. Assim, este estudo tem como objetivo revisar e discutir o tema, levando em consideração os fatores relacionados à lesão renal na COVID-19, bem como aspectos farmacocinéticos e recomendações de doses dos principais medicamentos utilizados para COVID-19.SciELO PreprintsSciELO PreprintsSciELO Preprints2020-05-09info:eu-repo/semantics/preprintinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://preprints.scielo.org/index.php/scielo/preprint/view/38410.1590/SciELOPreprints.384porhttps://preprints.scielo.org/index.php/scielo/article/view/384/473Copyright (c) 2020 Tácio Lima, Lucas Nuneshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessLima, TácioNunes, Lucasreponame:SciELO Preprintsinstname:SciELOinstacron:SCI2020-05-08T01:35:48Zoai:ops.preprints.scielo.org:preprint/384Servidor de preprintshttps://preprints.scielo.org/index.php/scieloONGhttps://preprints.scielo.org/index.php/scielo/oaiscielo.submission@scielo.orgopendoar:2020-05-08T01:35:48SciELO Preprints - SciELOfalse |
dc.title.none.fl_str_mv |
Pharmacotherapy for COVID-19 treatment in patients with renal impairment: a updated review Medicamentos utilizados no tratamento da COVID-19 em pacientes com insuficiência renal: uma atualização |
title |
Pharmacotherapy for COVID-19 treatment in patients with renal impairment: a updated review |
spellingShingle |
Pharmacotherapy for COVID-19 treatment in patients with renal impairment: a updated review Lima, Tácio COVID-19 insuficiência renal tratamento farmacológico ajuste de dose COVID-19 renal insufficiency drug therapy dosing adjustments |
title_short |
Pharmacotherapy for COVID-19 treatment in patients with renal impairment: a updated review |
title_full |
Pharmacotherapy for COVID-19 treatment in patients with renal impairment: a updated review |
title_fullStr |
Pharmacotherapy for COVID-19 treatment in patients with renal impairment: a updated review |
title_full_unstemmed |
Pharmacotherapy for COVID-19 treatment in patients with renal impairment: a updated review |
title_sort |
Pharmacotherapy for COVID-19 treatment in patients with renal impairment: a updated review |
author |
Lima, Tácio |
author_facet |
Lima, Tácio Nunes, Lucas |
author_role |
author |
author2 |
Nunes, Lucas |
author2_role |
author |
dc.contributor.author.fl_str_mv |
Lima, Tácio Nunes, Lucas |
dc.subject.por.fl_str_mv |
COVID-19 insuficiência renal tratamento farmacológico ajuste de dose COVID-19 renal insufficiency drug therapy dosing adjustments |
topic |
COVID-19 insuficiência renal tratamento farmacológico ajuste de dose COVID-19 renal insufficiency drug therapy dosing adjustments |
description |
COVID-19 has been identified the cause of several cases of pneumonia in China. The etiologic agent of the disease (SARS-CoV-2 virus) has a binding structure to the angiotensin-converting enzyme 2 (ACE2) receptor, allowing entry into cells that express ACE2, such as pulmonary alveolar epithelial cells. However, studies also show the possibility of damage of renal cells since these cells express high levels of ACE2. Currently, there is no evidence to indicate a specific treatment for COVID-19. Several drugs have been used and some of them may altered the elimination process in patients with renal impairment. To date, there are no studies that assist health professionals in dosing adjustment of these drugs. Thus, this study aimed to review and discuss the issue, considering the factors related to kidney injury in COVID-19, as well as pharmacokinetic aspects and dose recommendations of majority of drugs used for COVID-19. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-05-09 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/preprint info:eu-repo/semantics/publishedVersion |
format |
preprint |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://preprints.scielo.org/index.php/scielo/preprint/view/384 10.1590/SciELOPreprints.384 |
url |
https://preprints.scielo.org/index.php/scielo/preprint/view/384 |
identifier_str_mv |
10.1590/SciELOPreprints.384 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://preprints.scielo.org/index.php/scielo/article/view/384/473 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2020 Tácio Lima, Lucas Nunes https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2020 Tácio Lima, Lucas Nunes https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
SciELO Preprints SciELO Preprints SciELO Preprints |
publisher.none.fl_str_mv |
SciELO Preprints SciELO Preprints SciELO Preprints |
dc.source.none.fl_str_mv |
reponame:SciELO Preprints instname:SciELO instacron:SCI |
instname_str |
SciELO |
instacron_str |
SCI |
institution |
SCI |
reponame_str |
SciELO Preprints |
collection |
SciELO Preprints |
repository.name.fl_str_mv |
SciELO Preprints - SciELO |
repository.mail.fl_str_mv |
scielo.submission@scielo.org |
_version_ |
1797047817303228416 |